Clinical Research

Outcomes of Meningioma Patients Undergoing Stereotactic Radiotherapy

Volume: 13 Number: 3 May 31, 2023
EN TR

Outcomes of Meningioma Patients Undergoing Stereotactic Radiotherapy

Abstract

Aim: Innovations in radiotherapy have paved the way for alternative approaches for the treatment of meningioma, and in this context, radiosurgery has begun to be used in the treatment of meningioma. This study aimed to examine the clinical results of radiosurgery in the treatment of meningioma and to show whether it achieves the main goals, especially in terms of the possibility of tumor control and the success of preventing progression. Materials and Methods: Primary, residual, and recurrent meningioma treated with stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) between 2013 and 2020 were evaluated retrospectively. Study endpoints were overall survival (OS), progression free survival (PFS), and local control (LC). Results: 73 patients and 81 lesions were analyzed. The median duration of the follow-up period was 49 months (range, 7–138 months). 5- and 7-y OS and PFS were 87.6%, 78.9%; 82.9% and 82.9%, respectively. The tumor control rate was 94.6%. In univariate analysis, gender (p=0.007), radiosurgery for recurrence (p=0.011) and number of lesions (p=0.030) were found to be factors affecting OS, and number of lesions (p<0.001), grade (p=0.048) and tumor size (p=0.047) were found to be factors affecting PFS. Number of lesions (p=0.022) was remained prognostic factor for PFS in the multivariate analysis. Conclusion: Since SRS/SRT can provide high tumor control in the management of meningioma, it can be preferred as an alternative treatment method, especially in patients who are diagnosed radiologically, who are not candidates for surgery or who refuse surgical treatment, as well as in cases of residual and recurrence in the post-surgical period.

Keywords

References

  1. 1. Kohler BA, Ward E, McCarthy BJ et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011;103(9):714-36. doi: 10.1093/jnci/djr077.
  2. 2. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957;20(1):22-39. doi: 10.1136/jnnp.20.1.22.
  3. 3. Goldbrunner R, Stavrinou P, Jenkinson MD et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021;23(11):1821-34. doi: 10.1093/neuonc/noab150.
  4. 4. Valentino V. Radiosurgery in cerebral tumours and AVM. Acta Neurochir Suppl (Wien) 1988;42:193-7. doi: 10.1007/978-3-7091-8975-7_38.
  5. 5. Bir SC, Patra DP, Maiti TK, Bollam P, Minagar A, Nanda A. Direct Comparison of Gamma Knife Radiosurgery and Microsurgery for Small Size Meningiomas. World Neurosurg 2017;101:170-9. doi: 10.1016/j.wneu.2017.01.105.
  6. 6. DiBiase SJ, Kwok Y, Yovino S et al. Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas. Int J Radiat Oncol Biol Phys 2004;60(5):1515-9. doi: 10.1016/j.ijrobp.2004.05.073.
  7. 7. Kondziolka D, Mathieu D, Lunsford LD et al. Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery 2008;62(1):53-8; discussion 58-60. doi: 10.1227/01.NEU.0000311061.72626.0D.
  8. 8. Santacroce A, Walier M, Régis J et al. Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patients. Neurosurgery 2012;70(1):32-9; discussion 39. doi: 10.1227/NEU.0b013e31822d408a.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Clinical Research

Publication Date

May 31, 2023

Submission Date

March 1, 2023

Acceptance Date

April 2, 2023

Published in Issue

Year 2023 Volume: 13 Number: 3

APA
Delikgöz Soykut, E., Aksan, D., Şavlı, E., Yılmaz, S. B., & Tataroğlu, H. (2023). Outcomes of Meningioma Patients Undergoing Stereotactic Radiotherapy. Journal of Contemporary Medicine, 13(3), 426-432. https://doi.org/10.16899/jcm.1256587
AMA
1.Delikgöz Soykut E, Aksan D, Şavlı E, Yılmaz SB, Tataroğlu H. Outcomes of Meningioma Patients Undergoing Stereotactic Radiotherapy. J Contemp Med. 2023;13(3):426-432. doi:10.16899/jcm.1256587
Chicago
Delikgöz Soykut, Ela, Dönay Aksan, Evrim Şavlı, Salih Buğra Yılmaz, and Hatice Tataroğlu. 2023. “Outcomes of Meningioma Patients Undergoing Stereotactic Radiotherapy”. Journal of Contemporary Medicine 13 (3): 426-32. https://doi.org/10.16899/jcm.1256587.
EndNote
Delikgöz Soykut E, Aksan D, Şavlı E, Yılmaz SB, Tataroğlu H (May 1, 2023) Outcomes of Meningioma Patients Undergoing Stereotactic Radiotherapy. Journal of Contemporary Medicine 13 3 426–432.
IEEE
[1]E. Delikgöz Soykut, D. Aksan, E. Şavlı, S. B. Yılmaz, and H. Tataroğlu, “Outcomes of Meningioma Patients Undergoing Stereotactic Radiotherapy”, J Contemp Med, vol. 13, no. 3, pp. 426–432, May 2023, doi: 10.16899/jcm.1256587.
ISNAD
Delikgöz Soykut, Ela - Aksan, Dönay - Şavlı, Evrim - Yılmaz, Salih Buğra - Tataroğlu, Hatice. “Outcomes of Meningioma Patients Undergoing Stereotactic Radiotherapy”. Journal of Contemporary Medicine 13/3 (May 1, 2023): 426-432. https://doi.org/10.16899/jcm.1256587.
JAMA
1.Delikgöz Soykut E, Aksan D, Şavlı E, Yılmaz SB, Tataroğlu H. Outcomes of Meningioma Patients Undergoing Stereotactic Radiotherapy. J Contemp Med. 2023;13:426–432.
MLA
Delikgöz Soykut, Ela, et al. “Outcomes of Meningioma Patients Undergoing Stereotactic Radiotherapy”. Journal of Contemporary Medicine, vol. 13, no. 3, May 2023, pp. 426-32, doi:10.16899/jcm.1256587.
Vancouver
1.Ela Delikgöz Soykut, Dönay Aksan, Evrim Şavlı, Salih Buğra Yılmaz, Hatice Tataroğlu. Outcomes of Meningioma Patients Undergoing Stereotactic Radiotherapy. J Contemp Med. 2023 May 1;13(3):426-32. doi:10.16899/jcm.1256587